{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:43:23Z","timestamp":1784648603982,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["heartrhythmopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm O2"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.hroo.2021.10.001","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T19:17:07Z","timestamp":1634066227000},"page":"642-650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"PA","title":["Atrial fibrillation associated with heart failure treated by a 2-lead CRT-DX system (BIO-AffectDX): Study design and clinical protocol"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1523-573X","authenticated-orcid":false,"given":"Jonathan C.","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron B.","family":"Hesselson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson J.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Mountantonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory T.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Costea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hroo.2021.10.001_bib1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.108.821306","article-title":"Atrial fibrillation and heart failure: treatment considerations for a dual epidemic","volume":"19","author":"Anter","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.10.001_bib2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.hrthm.2017.03.024","article-title":"Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial","volume":"14","author":"Kalscheur","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hroo.2021.10.001_bib3","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.10.001_bib4","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/eurheartj\/ehl099","article-title":"Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the Cardiac Resynchronization-Heart Failure (CARE-HD) trial extension phase]","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hroo.2021.10.001_bib5","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1001\/jama.297.22.2502","article-title":"Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review","volume":"297","author":"McAlister","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.hroo.2021.10.001_bib6","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1161\/CIR.0b013e3182618569","volume":"14","author":"Tracy","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.10.001_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0735-1097(98)00221-6","article-title":"Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm","volume":"32","author":"Pozzoli","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2021.10.001_bib8","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1053\/euhj.1999.2107","article-title":"Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure","volume":"21","author":"Crijns","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hroo.2021.10.001_bib9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/eurjhf\/hfp085","article-title":"A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure","volume":"7","author":"Mamas","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hroo.2021.10.001_bib10","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1540-8159.2007.00872.x","article-title":"Cardiac resynchronization therapy response is associated with shorter duration of atrial fibrillation","volume":"30","author":"Lellouche","year":"2007","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hroo.2021.10.001_bib11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1540-8167.2006.00482.x","article-title":"Atrial fibrillation burden during the post-implant period after CRT using device-based diagnostics","volume":"17","author":"Hugl","year":"2006","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hroo.2021.10.001_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ahj.2020.02.011","article-title":"Future research prioritization in cardiac resynchronization therapy","volume":"223","author":"Fudim","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.hroo.2021.10.001_bib13","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/eurheartj\/ehn133","article-title":"Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation","volume":"29","author":"Gasparini","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hroo.2021.10.001_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jacc.2008.09.043","article-title":"Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary?","volume":"53","author":"Koplan","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2021.10.001_bib15","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.hrthm.2011.04.015","article-title":"Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival","volume":"8","author":"Hayes","year":"2011","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hroo.2021.10.001_bib16","first-page":"737","article-title":"Predictors of super-response to cardiac resynchronization therapy: the significance of heart failure medication, pre-implant left ventricular geometry and high percentage of biventricular pacing","volume":"14","author":"Jin","year":"2017","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.hroo.2021.10.001_bib17","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jacc.2008.12.022","article-title":"The utility of 12-lead holter monitoring in patients with permanent atrial fibrillation for the identification of nonresponders after cardiac resynchronization therapy","volume":"53","author":"Kamath","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2021.10.001_bib18","first-page":"634e41","article-title":"Variation in use of dual-chamber implantable cardioverter-defibrillators","volume":"172","author":"Matlock","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hroo.2021.10.001_bib19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jacc.2011.04.039","article-title":"Dual-chamber implantable cardioverter-defibrillator selection is associated with increase complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry","volume":"58","author":"Dewland","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2021.10.001_bib20","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1001\/jama.2013.4982","article-title":"Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention","volume":"309","author":"Peterson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.hroo.2021.10.001_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.115.003806","article-title":"Survival after rate-responsive programming in patients with cardiac resynchronization therapy-defibrillator implants is associated with a novel parameter: the heart rate score","volume":"9","author":"Olshansky","year":"2016","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hroo.2021.10.001_bib22","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.hrthm.2012.07.025","article-title":"2012 EHRA\/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management","volume":"9","author":"Daubert","year":"2012","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hroo.2021.10.001_bib23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jce.14396","article-title":"The role of atrial sensing for new-onset atrial arrhythmias diagnosis and management in single-chamber implantable cardioverter-defibrillator recipients: results from the THINGS registry","volume":"31","author":"Biffi","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hroo.2021.10.001_bib24","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/jce.14552","article-title":"Novel two-lead cardiac resynchronization therapy system provides equivalent CRT responses with less complications than a conventional three-lead system: results from the QP ExCELs lead registry","volume":"31","author":"Shaik","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hroo.2021.10.001_bib25","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/eurheartj\/ehp572","article-title":"Resumption of sinus rhythm in patients with heart failure and permanent atrial fibrillation undergoing cardiac resynchronization therapy: a longitudinal observational study","volume":"31","author":"Gasparini","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hroo.2021.10.001_bib26","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/jce.14081","article-title":"Subclinical atrial fibrillation detection with a floating atrial sensing dipole in single lead implantable cardioverter-defibrillator systems: results of the SENSE trial","volume":"30","author":"Thomas","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hroo.2021.10.001_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1054\/jcaf.2001.25652","article-title":"Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure","volume":"7","author":"Packer","year":"2001","journal-title":"J Card Fail"},{"key":"10.1016\/j.hroo.2021.10.001_bib28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ejhf.698","article-title":"Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure","volume":"19","author":"Packer","year":"2017","journal-title":"Eur J Heart Fail"}],"container-title":["Heart Rhythm O2"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501821001963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501821001963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:25:40Z","timestamp":1762993540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666501821001963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2666501821001963"],"URL":"https:\/\/doi.org\/10.1016\/j.hroo.2021.10.001","relation":{},"ISSN":["2666-5018"],"issn-type":[{"value":"2666-5018","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atrial fibrillation associated with heart failure treated by a 2-lead CRT-DX system (BIO-AffectDX): Study design and clinical protocol","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm O2","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hroo.2021.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Heart Rhythm Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}